StockData

Ascentage Pharma Group International vs OPKO Health

AAPG and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and OPK compare

OPKO Health grew revenue faster over the last twelve months (−11.5% versus −41.5% for Ascentage Pharma Group International).

OPKO Health keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −216% at Ascentage Pharma Group International.

OPKO Health scores higher on the StockData Score (9 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGOPK
Size and price
Market cap–$1.2B
Share price$13.14$1.62
Change, 1 year−61.7%26.6%
Change, 5 years–−60.8%
Beta (5Y)1.430.36
Employees7672,275
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score11
Performance score13 (better)
Health score14 (better)
Dividend score00
Valuation
P/S–2.1×
P/B–1.0×
EV/EBITDA–22.0×
FCF yield–−11.1%
Fair value–$1.55
Margin of safety–−4.7%
Growth
Revenue growth (TTM)−41.5%−11.5% (better)
Revenue growth, 5Y average–−15.8%
Profitability
Gross margin91.5% (better)40.8%
Operating margin–−8.2%
Net margin−216%−12.4% (better)
FCF margin−209%−22.8% (better)
Return on equity−156%−5.9% (better)
Return on invested capital–−4.0%
Financial health
Debt / equity1.500.00 (better)
Net debt / EBITDA–−7.19
Current ratio1.793.35 (better)
Altman Z-score–−0.21
Piotroski F-score–4
Dividends and buybacks
Buyback yield–3.9%
Shareholder yield–3.9%
Ownership
Held by institutions0.00%27.2%
Held by insiders13.0%43.6%
Insider net buying, 12 months–−$13.2K
Short interest, % of float–7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.